Nexalin announced an exclusive distribution agreement with Carmi Masha Technologies Ltd. for its Gen‑2 SYNC neurostimulation device in Israel, following the Israeli Ministry of Health’s approval of the product on October 30, 2025.
Under the terms of the agreement, Carmi Masha will handle sales, marketing, clinical education, importation, registration and distribution across hospitals, clinics and private treatment centers, allowing Nexalin to monetize the regulatory clearance quickly and scale the device’s reach in a receptive market.
The Gen‑2 SYNC is a 15‑milliamp, non‑invasive neurostimulation system approved for insomnia, depression and anxiety. The partnership positions Nexalin to expand into additional indications such as PTSD, traumatic brain injury and Alzheimer’s disease within Israel’s advanced healthcare ecosystem.
The original article cited a 1054.4% surge in China sales, a figure that could not be corroborated by available sources. Nexalin has received regulatory approval in China, but specific sales data are not publicly disclosed. The company recently closed a $5 million public offering, indicating ongoing capital raising to support its global expansion.
Israel is a high‑value early‑adopter market for mental‑health innovations, with a sizable patient population receptive to drug‑free treatments. Carmi Masha’s established network provides immediate access to providers and patients, potentially accelerating adoption of the Gen‑2 SYNC device.
The deal aligns with Nexalin’s broader international strategy, which has seen significant growth in China and the launch of a virtual clinic for its HALO headset. By diversifying beyond paused U.S. Gen‑1 sales, Nexalin reduces reliance on a single market and positions itself for future therapeutic applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.